BACKGROUND: T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive disease. In this study, we report our experience from 119 patients with T-PLL. PATIENTS AND METHODS: We reviewed the clinico-pathologic records of 119 consecutive patients with T-PLL, who presented to our institution between 1990 and 2016. RESULTS: One hundred and nineteen patients with T-PLL were analysed. Complex karyotype and aberrations in chromosome 14 were seen in 65% and 52% patients, respectively. Seventy-five patients (63%) were previously untreated and 43 (37%) were initially treated outside our institution. Sixty-three previously untreated patients (84%) received frontline therapies. Overall, 95 patients (80%) have died. Median overall survival (OS) from diagnosis was 19 months [95% confidence interval (CI) 16-26 months]. Using recursive partitioning (RP), we found that patients with hemoglobin < 9.3 g/dl, lactate dehydrogenase (LDH) ≥ 1668 IU/l, white blood cell ≥ 208 K/l and β2M ≥ 8 mg/l had significantly inferior OS and patients with hemoglobin < 9.3 g/dl had inferior progression-free survival (PFS). In multivariate analysis, we identified that presence of pleural effusion [hazard ratio (HR) 2.08 (95% CI 1.11-3.9); P = 0.02], high LDH (≥ 1668 IU/l) [HR 2.5 (95% CI 1.20-4.24); P < 0.001)], and low hemoglobin (< 9.3 g/dl) [HR 0.33 (95% CI 0.14-0.75); P = 0.008] were associated with shorter OS. Fifty-five previously untreated patients received treatment with an alemtuzumab-based regimen (42 monotherapy and 13 combination with pentostatin). Overall response rate, complete remission rate (CR) for single-agent alemtuzumab and alemtuzumab combined with pentostatin were 83%, 66% and 82%, 73% respectively. In patients who achieved initial CR, stem cell transplantation was not associated with longer PFS and OS. CONCLUSION: Outcomes in T-PLL remain poor. Multicenter collaborative effort is required to conduct prospective studies.
BACKGROUND: T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive disease. In this study, we report our experience from 119 patients with T-PLL. PATIENTS AND METHODS: We reviewed the clinico-pathologic records of 119 consecutive patients with T-PLL, who presented to our institution between 1990 and 2016. RESULTS: One hundred and nineteen patients with T-PLL were analysed. Complex karyotype and aberrations in chromosome 14 were seen in 65% and 52% patients, respectively. Seventy-five patients (63%) were previously untreated and 43 (37%) were initially treated outside our institution. Sixty-three previously untreated patients (84%) received frontline therapies. Overall, 95 patients (80%) have died. Median overall survival (OS) from diagnosis was 19 months [95% confidence interval (CI) 16-26 months]. Using recursive partitioning (RP), we found that patients with hemoglobin < 9.3 g/dl, lactate dehydrogenase (LDH) ≥ 1668 IU/l, white blood cell ≥ 208 K/l and β2M ≥ 8 mg/l had significantly inferior OS and patients with hemoglobin < 9.3 g/dl had inferior progression-free survival (PFS). In multivariate analysis, we identified that presence of pleural effusion [hazard ratio (HR) 2.08 (95% CI 1.11-3.9); P = 0.02], high LDH (≥ 1668 IU/l) [HR 2.5 (95% CI 1.20-4.24); P < 0.001)], and low hemoglobin (< 9.3 g/dl) [HR 0.33 (95% CI 0.14-0.75); P = 0.008] were associated with shorter OS. Fifty-five previously untreated patients received treatment with an alemtuzumab-based regimen (42 monotherapy and 13 combination with pentostatin). Overall response rate, complete remission rate (CR) for single-agent alemtuzumab and alemtuzumab combined with pentostatin were 83%, 66% and 82%, 73% respectively. In patients who achieved initial CR, stem cell transplantation was not associated with longer PFS and OS. CONCLUSION: Outcomes in T-PLL remain poor. Multicenter collaborative effort is required to conduct prospective studies.
Authors: Cristina López; Anke K Bergmann; Ulrike Paul; Eva M Murga Penas; Inga Nagel; Matthew J Betts; Patricia Johansson; Matthias Ritgen; Tycho Baumann; Marta Aymerich; Sandrine Jayne; Robert B Russell; Elias Campo; Martin J S Dyer; Jan Dürig; Reiner Siebert Journal: Br J Haematol Date: 2016-02-25 Impact factor: 6.998
Authors: Farhad Ravandi; Susan O'Brien; Dan Jones; Susan Lerner; Stefan Faderl; Alessandra Ferrajoli; William Wierda; Guillermo Garcia-Manero; Deborah Thomas; Charles Koller; Srdan Verstovsek; Francis Giles; Jorge Cortes; Marco Herling; Hagop Kantarjian; Michael Keating Journal: Clin Lymphoma Myeloma Date: 2005-11
Authors: C E Dearden; E Matutes; B Cazin; G E Tjønnfjord; A Parreira; B Nomdedeu; P Leoni; F J Clark; D Radia; S M Rassam; T Roques; N Ketterer; V Brito-Babapulle; M J Dyer; D Catovsky Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: L Sellner; M Brüggemann; M Schlitt; H Knecht; D Herrmann; T Reigl; A Krejci; V Bystry; N Darzentas; M Rieger; S Dietrich; T Luft; A D Ho; M Kneba; P Dreger Journal: Bone Marrow Transplant Date: 2016-12-12 Impact factor: 5.483
Authors: Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones Journal: Blood Date: 2007-09-21 Impact factor: 22.113
Authors: M G Narducci; L Virgilio; M Isobe; A Stoppacciaro; R Elli; M Fiorilli; M Carbonari; A Antonelli; L Chessa; C M Croce; G Russo Journal: Blood Date: 1995-09-15 Impact factor: 22.113
Authors: Philipp B Staber; Marco Herling; Mar Bellido; Eric D Jacobsen; Matthew S Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden Journal: Blood Date: 2019-07-10 Impact factor: 22.113
Authors: Hemant S Murthy; Kwang Woo Ahn; Noel Estrada-Merly; Hassan B Alkhateeb; Susan Bal; Mohamed A Kharfan-Dabaja; Bhagirathbhai Dholaria; Francine Foss; Lohith Gowda; Deepa Jagadeesh; Craig Sauter; Muhammad Bilal Abid; Mahmoud Aljurf; Farrukh T Awan; Ulrike Bacher; Sherif M Badawy; Minoo Battiwalla; Chris Bredeson; Jan Cerny; Saurabh Chhabra; Abhinav Deol; Miguel Angel Diaz; Nosha Farhadfar; César Freytes; James Gajewski; Manish J Gandhi; Siddhartha Ganguly; Michael R Grunwald; Joerg Halter; Shahrukh Hashmi; Gerhard C Hildebrandt; Yoshihiro Inamoto; Antonio Martin Jimenez-Jimenez; Matt Kalaycio; Rammurti Kamble; Maxwell M Krem; Hillard M Lazarus; Aleksandr Lazaryan; Joseph Maakaron; Pashna N Munshi; Reinhold Munker; Aziz Nazha; Taiga Nishihori; Olalekan O Oluwole; Guillermo Ortí; Dorothy C Pan; Sagar S Patel; Attaphol Pawarode; David Rizzieri; Nakhle S Saba; Bipin Savani; Sachiko Seo; Celalettin Ustun; Marjolein van der Poel; Leo F Verdonck; John L Wagner; Baldeep Wirk; Betul Oran; Ryotaro Nakamura; Bart Scott; Wael Saber Journal: Transplant Cell Ther Date: 2022-01-23
Authors: Ali Sakhdari; Guilin Tang; Lawrence E Ginsberg; Cheryl F Hirsch-Ginsberg; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Roberto N Miranda Journal: Case Rep Pathol Date: 2019-03-03
Authors: Till Braun; Markus Glass; Linus Wahnschaffe; Moritz Otte; Petra Mayer; Marek Franitza; Janine Altmüller; Michael Hallek; Stefan Hüttelmaier; Alexandra Schrader; Marco Herling Journal: Haematologica Date: 2022-01-01 Impact factor: 9.941